Success Metrics

Clinical Success Rate

87.3%

Based on 55 completed trials

Completion Rate

87%(55/63)

Active Trials

22(19%)

Results Posted

40%(22 trials)

Terminated

8(7%)

Phase Distribution

Ph phase_4

Ph phase_2

43%

Ph phase_1

27%

Ph early_phase_1

Ph phase_3

Ph not_applicable

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution109 total trials

Early Phase 1First-in-human

9(8.3%)

Phase 1Safety & dosage

31(28.4%)

Phase 2Efficacy & side effects

49(45.0%)

Phase 3Large-scale testing

7(6.4%)

Phase 4Post-market surveillance

4(3.7%)

N/ANon-phased studies

9(8.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

76.4%

55 of 72 finished

Non-Completion Rate

23.6%

17 ended early

Currently Active

trials recruiting

Total Trials

114

all time

Status Distribution

Active(26)

Completed(55)

Terminated(17)

Other(16)

Detailed Status

Completed55

Recruiting18

unknown16

Withdrawn9

Terminated8

Active, not recruiting4

Development Timeline

Analytics

Development Status

Total Trials

114

Active

Success Rate

87.3%

Most Advanced

Phase 4

Trials by Phase

Early Phase 19 (8.3%)

Phase 131 (28.4%)

Phase 249 (45.0%)

Phase 37 (6.4%)

Phase 44 (3.7%)

N/A9 (8.3%)

Trials by Status

unknown1614%

withdrawn98%

completed5548%

active_not_recruiting44%

recruiting1816%

not_yet_recruiting44%

terminated87%

Recent Activity

22 active trials

Showing 5 of 114

recruitingphase_2

Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

NCT05044819

recruitingphase_2

Evaluating the Impact of a Novel Cannabinoid Product for Endometriosis

NCT06477406

View all 114 trials

Clinical Trials (114)

Showing 20 of 114 trialsScroll for more

NCT07549256Phase 2

Cannabidiol for Pain Relief of Patients With End-stage mCRPC

Recruiting

NCT06381180Phase 1

Warrior CARE: Cannabis Behavioral Health

Recruiting

NCT04978428Phase 2

Epidiolex in Obsessive Compulsive Disorder and Related Disorders

Completed

NCT05044819Phase 4

Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

Active Not Recruiting

NCT06477406Phase 2

Evaluating the Impact of a Novel Cannabinoid Product for Endometriosis

Recruiting

NCT05613608Phase 2

Alcohol Use Disorder and Cannabidiol

Recruiting

NCT05822362Phase 2

CBD for Individuals at Risk for Alzheimer's Disease

Recruiting

NCT07527338Phase 2

Mechanisms of Cannabidiol and Sleep in the Context of Alcohol Use

Not Yet Recruiting

NCT07624279Phase 2

nVNS, CBD, and SoC for Persistent Post-Traumatic Headache

Not Yet Recruiting

NCT06213233Phase 2

MIVetsCan: Cannabidiol (CBD)-Care Trial

Recruiting

NCT04749628Phase 4

Cannabidiol for Bilateral Total Knee Arthroplasty

Completed

NCT03518801Phase 2

Cannabidiol and Prolonged Exposure

Completed

NCT07564245Phase 2

Efficacy of Cannabidiol in the Management of Self-injuries in Children and Adolescents With Severe Neurodevelopmental Disorders.

Not Yet Recruiting

NCT03984565Phase 2

PAIN: A Project Assessing the Impact of a Novel Cannabinoid Product

Recruiting

NCT05457465Phase 2

Assessing the Impact of Cannabidiol for Anxiety and Depression in Bipolar Disorder

Recruiting

NCT05942911Phase 2

Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis

Terminated

NCT05651607Phase 2

Evaluation of the Efficacy of CANNABIDIOL on the Pruritus in Children With Hereditary Epidermolysis Bullosa

Completed

NCT04550377Phase 2

Cannabidiol as a Treatment for PTSD and PTSD Comorbid With TBI

Recruiting

NCT06854783Phase 1

Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers

Completed

NCT04105231Phase 2

Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use

Active Not Recruiting

Drug Details

Intervention Type: DRUG
Total Trials: 114